Latest News and Press Releases

Aphaia’s lead formulation orchestrates a comprehensive hormonal response from nutrient-sensing cells with potential to modify the course of obesity and associated metabolic diseases.It is currently...

Second Phase 2 trial builds on encouraging initial results from a prior Phase 2 studyAphaia’s formulation activates gastrointestinal nutrient-sensing signaling pathways to modify the course of obesity...

ZUG, Switzerland and SAN JUAN, Puerto Rico and TORONTO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore...

ZUG, Switzerland and SAN JUAN, Puerto Rico and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore...

ZUG, Switzerland and SAN JUAN, Puerto Rico and TORONTO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore...

Primary endpoint met, showing that APHD-012 improves glucose tolerance in individuals with a pathological oral glucose tolerance test (OGTT) after 6 weeks of administrationThe results provide...

Enrollment has been completed for the last four cohorts evaluating the contribution of circadian effects in weight loss treatment using Aphaia’s formulationTopline data anticipated in Q3 and Q4 2024...

Enrollment has been completed for the first two cohorts evaluating a once-daily 12g dose of its oral glucose formulation (APHD-012)The company is expanding its trial protocol to further explore the...

ZUG, Switzerland and SAN JUAN, Puerto Rico and TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore...

ZUG, Switzerland and SAN JUAN, Puerto Rico, April 25, 2023 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous...